Skip to main content

Advertisement

SpringerLink
Log in

Paclitaxel plus carboplatin–induced peripheral neuropathy

A prospective clinical and electrophysiological study in patients suffering from solid malignancies

  • ORIGINAL COMMUNICATION
  • Published:
Journal of Neurology Aims and scope Submit manuscript

Abstract

Objective

The current study intended to determine the incidence, severity and reversibility of paclitaxel plus carboplatin (CP)–induced peripheral neuropathy (CPPN) and to describe its clinical and electrophysiological features.

Patients and methods

We prospectively studied 21 adult patients scheduled to be treated with 6 courses of cumulative carboplatin plus paclitaxel (CP) regimens for a non–myeloid malignancy. They were followed–up by neurological examination and electrophysiological study during chemotherapy and 3 months after its discontinuation. The severity of neurotoxicity was assessed by means of a modified peripheral neuropathy (PNP) score.

Results

Evidence of CPPN was recorded in 14 of the 21 patients (66.6 %). The sensory symptoms were present in the lower limbs first and then involved the upper limbs. No statistical significance, concerning the changes from baseline to subsequent mean scores in all motor conduction parameters examined,was revealed. By contrast, comparisons of the mean changes at baseline and each of the follow–up studies showed significant decrease in all sensory action potentials examined. The mean PNP scores for patients that manifested some grade of neurotoxicity were 17.9 ± 9.8. The followup data 3 months after the discontinuation of chemotherapy showed that the CP–induced neuropathy was at least partially reversed.

Conclusions

CP–induced neuropathy was symmetrical, distal and predominately sensory in character, though minor to moderate motor signs were only evident in severely affected patients. Reversibility of CPinduced neuropathy was partially observed after the suspension of chemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Argyriou AA, Chroni E, Koutras A, et al. (2005) Vitamin E for prophylaxis against chemotherapy–induced neuropathy: a randomized controlled trial. Neurology 64(1):26–31

    PubMed  CAS  Google Scholar 

  2. Argyriou AA, Polychronopoulos P, Koutras A, et al. (2005) Peripheral neuropathy induced by administration of cisplatin and paclitaxel–based chemotherapy. Could it be predicted? Support Care Cancer 13(8):647–651

    Article  PubMed  Google Scholar 

  3. Berger T, Malayeri R, Doppelbauer G, et al. (1997) Neurological monitoring of neurotoxicity induced by paclitaxel/ cisplatin chemotherapy. Eur J Cancer 33(9):1393–1399

    Article  PubMed  CAS  Google Scholar 

  4. Chaudhry V, Rowinsky EK, Sartorius SE, et al. (1994) Peripheral neuropathy from taxol and cisplatin combination chemotherapy: Clinical and electrophysiological studies. Ann Neurol 35:304–311

    Article  PubMed  CAS  Google Scholar 

  5. Davidson NG (1996) Single–agent paclitaxel as first–line treatment of metastatic breast cancer: the British experience. Semin Oncol 23(suppl 11):6–10

    PubMed  CAS  Google Scholar 

  6. Dustin P (1980) Microtubules. Sci Am 243:66–76

    Article  PubMed  CAS  Google Scholar 

  7. du Bois A, Luck HJ, Meier W, et al. (2003) Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer Study Group. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/ paclitaxel as first–line treatment of ovarian cancer. J Natl Cancer Inst 95(17):1320–1329

    PubMed  CAS  Google Scholar 

  8. Dyck PJ, Thomas PK (1993) (eds): Peripheral Neuropathy (ed 3). Vol 2. Philadelphia, PA, WB Saunders, pp 1310–1317

  9. Fountzilas G, Kalofonos HP, Dafni U, et al. (2004) Paclitaxel and epirubicin versus paclitaxel and carboplatin as first–line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 15(10):1517–1526

    Article  PubMed  CAS  Google Scholar 

  10. Gore M, Mainwaring P, A’Hern R, et al. (1998) Randomized trial of dose–intensity with single–agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group. J Clin Oncol 16(7):2426–2434

    PubMed  CAS  Google Scholar 

  11. Huizing MT, van Warmerdam LJ, Rosing H, et al. (1997) Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first–line chemotherapy in stage III and IV ovarian cancer. J Clin Oncol 15(5):1953–1964

    PubMed  CAS  Google Scholar 

  12. Kimura J (2001) Electrodiagnosis in diseases of nerve and muscle, principles and practice (ed 3). Oxford University press, pp 91–166

  13. Kleyweg RP, Van der Meché FGA, Schmitz PIM (1991) Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain–Barré syndrome. Muscle Nerve 14:1103–1109

    Article  PubMed  CAS  Google Scholar 

  14. Lilenbaum RC, Chen CS, Chidiac T, et al. (2005) Phase II randomized trial of vinorelbine and gemcitabine versus carboplatin and paclitaxel in advanced non–small–cell lung cancer. Ann Oncol 16(1):97–101

    Article  PubMed  CAS  Google Scholar 

  15. Markman M, Kennedy A, Webster K, et al. (2001) Neurotoxicity associated with a regimen of carboplatin (AUC 5–6) and paclitaxel (175 mg/m2 over 3 h) employed in the treatment of gynecologic malignancies. J Cancer Res Clin Oncol 127(1):55–58

    Article  PubMed  CAS  Google Scholar 

  16. McGuire WP (1997) How many more nails to seal the coffin of dose intensity? Ann Oncol 8(4):311–313

    PubMed  CAS  Google Scholar 

  17. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207–214

    PubMed  CAS  Google Scholar 

  18. Ozols RF, Bundy BN, Greer BE, et al. (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21(17):3194–3200

    PubMed  CAS  Google Scholar 

  19. Panayiotopoulos CP, Chroni E (1996) F–waves in clinical neurophysiology: a review. Methodological issues and overall value in peripheral neuropathies. Electroencephalogr Clin Neurophysiol 101:365–374

    PubMed  CAS  Google Scholar 

  20. Peltier AC, Russell JW (2002) Recent advances in drug–induced neuropathies. Curr Opin Neurol 15(5):633–638

    Article  PubMed  Google Scholar 

  21. Quasthoff S, Hartung HP (2002) Chemotherapy–induced peripheral neuropathy. J Neurol 249(1):9–17

    PubMed  CAS  Google Scholar 

  22. Rowinsky EK, Cazenave LA, Donehower RC (1990) Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 82:1247–1259

    PubMed  CAS  Google Scholar 

  23. Rowinsky EK, Eisenhauer EA, Chaudhry V, et al. (1993) Clinical toxicities encountered by paclitaxel (Taxol). Semin Oncol 20:1–15

    PubMed  CAS  Google Scholar 

  24. Rowinsky EK, Donehower RC (1995) Paclitaxel (Taxol). NEJM 332:1004–1014

    Article  PubMed  CAS  Google Scholar 

  25. Schaumburg HH, Spencer PS (1979) Toxic neuropathies. Neurology 29:429–431

    PubMed  CAS  Google Scholar 

  26. Thigpen JT (1997) Dose–intensity in ovarian carcinoma: hold, enough? J Clin Oncol 15(4):1291–1293

    PubMed  CAS  Google Scholar 

  27. Windebank AJ (1999) Chemotherapeutic neuropathy. Curr Opin Neurol 12:565–571

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dept. of Neurology, Laboratory of Clinical Neurophysiology, University of Patras Medical School, 1045, Rion, Patras, Greece

    A. A. Argyriou MD, P. Polychronopoulos MD & E. Chroni MD, PhD

  2. Dept. of Medicine, Division of Oncology, University of Patras Medical School, Rion–Patras, Greece

    G. Iconomou PhD, A. Koutras MD, PhD & H. P. Kalofonos MD, PhD

Authors
  1. A. A. Argyriou MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Polychronopoulos MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Iconomou PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Koutras MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H. P. Kalofonos MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E. Chroni MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. A. Argyriou MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Argyriou, A.A., Polychronopoulos, P., Iconomou, G. et al. Paclitaxel plus carboplatin–induced peripheral neuropathy. J Neurol 252, 1459–1464 (2005). https://doi.org/10.1007/s00415-005-0887-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-005-0887-8

Key words

Search

Navigation